Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS

Area of Science:

• Cardiology
• Pharmacogenomics
• Clinical Risk Stratification

Background:

• Clopidogrel is a P2Y12 inhibitor widely used for acute coronary syndrome (ACS).
• High platelet reactivity (HPR) during clopidogrel therapy is associated with increased risk of adverse cardiovascular events.
• Predictive tools are needed to identify ACS patients at risk for HPR and subsequent major adverse cardiovascular events (MACEs).

Purpose of the Study:

• To evaluate the ABCD-GENE score for identifying patients with HPR after clopidogrel treatment.
• To assess the association of the ABCD-GENE score with the risk of MACEs in ACS patients.
• To determine if adding 5-day HPR measurement improves the predictive ability of the ABCD-GENE score for MACEs.

Main Methods:

• A cohort of 1297 eligible ACS patients treated with clopidogrel was analyzed.
• The ABCD-GENE score was calculated and its association with 5-day HPR and 12-month MACEs was assessed.
• Multivariable analysis and c-statistic were used to evaluate the predictive performance of the score and the combined model.

Main Results:

• The ABCD-GENE score (cutoff ≥10) was independently associated with 5-day HPR (aHR: 1.73) and MACEs (aHR: 2.25).
• The risk of MACEs was significantly higher when the ABCD-GENE score was combined with 5-day HPR (aHR: 4.37).
• The c-statistic for MACE prediction was 0.60 for the score alone and improved to 0.63 with the addition of 5-day HPR.

Conclusions:

• The ABCD-GENE score is a simple tool to identify Chinese ACS patients treated with clopidogrel who are at increased risk of MACEs.
• The score effectively predicts both HPR and MACEs in this patient population.
• Incorporating 5-day HPR measurement into the ABCD-GENE score slightly enhances its diagnostic ability for predicting MACEs.